Publicacións en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (55)

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

  2. Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology

    Clinical and Translational Oncology

  3. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328

  4. Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study

    Clinical and Translational Oncology

  5. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871

  6. SEOM-GEM clinical guidelines for cutaneous melanoma (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2841-2855

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

  2. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  3. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

    Therapeutic Advances in Medical Oncology, Vol. 15

  4. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

  5. What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491

2022

  1. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

  2. SEOM—GECOD clinical guideline for unknown primary cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 681-692

2021

  1. Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study

    Advances in Therapy, Vol. 38, Núm. 1, pp. 290-303

  2. Case-control analysis of the impact of anemia on quality of life in patients with cancer: A Qca study analysis

    Cancers, Vol. 13, Núm. 11

  3. Epithelial-to-mesenchymal transition mediates resistance to maintenance therapy with vinflunine in advanced urothelial cell carcinoma

    Cancers, Vol. 13, Núm. 24

  4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  5. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553

  6. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 980-987

  7. Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1304-1313